Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc. experienced a significant growth in Q4'25, with NeXT Personal Dx volumes increasing by 41% quarter-over-quarter, driven by expectations of enhanced marketing efforts from their commercial partner, Tempus. Moreover, the recent announcement of Medicare coverage and pricing for the proprietary NeXT Personal MRD test, particularly in breast cancer, has led to a notable 28% rise in shares and reflects the test's strong performance in detecting minimal residual disease. Despite the stock's recent increase, assessments suggest that it remains undervalued when considering the potential market opportunities for its various genomic sequencing and analytics solutions.

Personalis Inc. faces a negative outlook due to a lowered revenue guidance for 2025, which estimates a decline of 12% to 5% year-over-year, driven primarily by reduced demand for pharma services linked to the completion of Moderna's Phase III melanoma trial. Furthermore, the company has encountered logistical challenges with global samples, further complicating its operational efficiency and revenue generation potential. Additionally, significant ongoing losses and the presence of debt on the balance sheet raise concerns about the sustainability of its business model and its ability to achieve profitability in the near future.